Latest Commercialization News

Income Asset Management has resolved a protracted legal dispute with BGC involving former employees, agreeing to a $1.9 million settlement. A key shareholder has stepped in with a liquidity facility to support the company’s payment obligations.

OncoSil Medical Ltd has launched an $8 million equity raising to fund the commercial expansion and clinical development of its targeted radiotherapy device for pancreatic cancer, aiming to capitalise on growing European market adoption and upcoming trial catalysts.

OncoSil Medical Limited has announced a fully underwritten $2 million entitlement offer alongside a $6 million placement to fund its clinical and commercial growth initiatives. The capital raising includes new shares and options, with shareholder approvals pending for certain components.

OncoSil Medical secures $8 million in capital to fund a pivotal German government-sponsored clinical trial and accelerate its European commercial expansion.

1414 Degrees has achieved a key milestone with its SiNTL silicon anode material reaching 500 mAh/g, matching current commercial standards ahead of schedule and setting sights on 600 mAh/g within a year.

CuFe, Emmerson, and Tennant Minerals have won $600,000 in matched government grants to fund a feasibility study for a shared critical minerals processing facility in Tennant Creek, aiming to boost regional mining development.

Barton Gold Holdings has kicked off its 2026 drilling campaign at the Tunkillia Gold Project, aiming to secure Ore Reserves, complete a pre-feasibility study, and lodge a Mining Lease application by the end of the year.

Sparc Technologies and the Australian Institute for Machine Learning are developing AI-driven software to transform protective coatings corrosion assessment, promising faster, more accurate results for a global market of testing labs.

Memphasys has lodged regulatory submissions for its Felix™ System in Australia and India, following CE Mark approval, while progressing UK market entry under the CE Mark transition framework.

Aroa Biosurgery’s latest business update reveals promising clinical outcomes from its Myriad trauma study and evolving reimbursement policies that could reshape its market position. The company also projects solid revenue growth for FY26, supported by strategic commercial initiatives.

Rhythm Biosciences has secured a multi-year commercial manufacturing agreement with US-based Quansys Biosciences to produce ColoSTAT® reagent kits, paving the way for broader market rollout of its colorectal cancer diagnostic test.

Credit Corp delivers steady H1 FY26 results with robust US collections and record lending volumes, while pursuing a strategic acquisition to boost its consumer finance footprint.